Radiation therapy in non-small-cell lung cancer

Michael Dohopolski, Sujana Gottumukkala, Daniel Gomez, Puneeth Iyengar

Research output: Contribution to journalArticlepeer-review

Abstract

The management of non-small-cell lung cancer (NSCLC) varies according to stage. Surgical resection is reserved for operable patients with early-stage NSCLC, while high-dose target radiation—stereotactic body radiation therapy (SBRT)—is reserved for patients whose comor-bidities prohibit them from a major surgical procedure. The treatment of locally advanced NSCLC (LA-NSCLC) is stratified according to resectability. Those with resectable disease may require additional treatments such as chemotherapy and radiation, while patients with un-resectable disease will require definitive chemoradiation therapy with adjuvant durvalumab. Patients with limited metastatic disease benefit from the combination of SBRT and systemic therapy.

Original languageEnglish (US)
Article numbera037713
JournalCold Spring Harbor Perspectives in Medicine
Volume11
Issue number10
DOIs
StatePublished - Oct 2021

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint

Dive into the research topics of 'Radiation therapy in non-small-cell lung cancer'. Together they form a unique fingerprint.

Cite this